منابع مشابه
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma LDLc. Here, we have developed active, cross-species, small interfering RNAs (siRNAs) capable of t...
متن کاملPCSK9 as a therapeutic target for cardiovascular disease
It is well recognized that the elevated plasma level of low-density lipoprotein-cholesterol (LDL-C) is a major risk factor for atherosclerosis and cardiovascular disease (CVD). Deposition of pro-atherogenic LDL-C, on the intima of arterial wall, contributes to plaque formation and atherosclerosis, which further leads to lowered blood flow to vital organs and increased risk of CVD. The most comm...
متن کاملThe Gains from Imperfect Inflation-Targeting Commitments
In a New-Keynesian sticky-price model, we study how the gains from commitments depend on their horizon and credibility. Continuously committing just one period ahead captures all the gains available for any strictly positive level of credibility, unless policymakers themselves exclude deviations, in which case a relatively high credibility is required just to capture the majority of these. The ...
متن کاملQuercetin: Antitumor Activity and Pharmacological Manipulations for Increased Therapeutic Gains
In the present study, we examined antiproliferative activity of quercetin in vitro and in vivo. Antiproliferative activity was demonstrated against MCF7 cell line in a dose and time dependent manner with IC50 value found to be 10 μg/ml. Further quercetin arrested MCF7 cells in G2/M phase of cell cycle in a dose and time dependent way. MCF-7 cells exposed to quercetin beta cyclodextrin complex s...
متن کاملPCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
PURPOSE OF REVIEW The first monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been approved for clinical use. This timely review highlights recent developments. RECENT FINDINGS Low-density lipoprotein cholesterol (LDL-C) is the primary driver of atherosclerosis and the key target for intervention. Yet despite best treatment including statins, attaining...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Atherosclerosis Reports
سال: 2015
ISSN: 1523-3804,1534-6242
DOI: 10.1007/s11883-015-0499-4